Literature DB >> 32105187

Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.

G E Cacciamani1, S Ghodoussipour1, A Mari2,3, K S Gill1, M Desai1, W Artibani4, P S Gill5, S F Shariat2,6,7,8, I S Gill1, H Djaladat1.   

Abstract

PURPOSE: Studies exploring the association of cigarette smoking and long-term survival outcomes following radical cystectomy have yielded mixed results. We performed a systematic review and meta-analysis to investigate the impact of tobacco smoking exposure, duration, intensity and cessation on response to neoadjuvant chemotherapy and long-term survival outcomes in patients undergoing radical cystectomy for bladder cancer.
MATERIALS AND METHODS: We systematically searched PubMed®, MEDLINE®, Embase® and Cochrane® Library databases for original articles published before April 2019. Primary end points were neoadjuvant chemotherapy response, overall and cancer specific mortality, and recurrence-free survival after radical cystectomy. Observational studies reporting Cox proportional hazards regression or logistic regression analysis were independently screened. Available multivariable hazard ratios and corresponding 95% CIs were included in the quantitative analysis. Sensitivity analyses were performed as appropriate. A risk of bias assessment was completed for nonrandomized studies.
RESULTS: Our electronic search identified a total of 649 articles. After a detailed review we selected 17 studies that addressed the impact of smoking status on survival outcomes in 13,777 patients after radical cystectomy for bladder cancer. Pooled meta-analysis revealed that active smokers have an increased risk of overall mortality (HR 1.21, 95% CI 1.08-1.36; p=0.001, I2=0%), cancer specific mortality (HR 1.24, 95% CI 1.13-1.36; p <0.00001, I2=0%) and bladder cancer recurrence (HR 1.24, 95% CI 1.12-1.38; p <0.0001, I2=3%). Sensitivity analyses evaluating only patients who underwent neoadjuvant chemotherapy followed by radical cystectomy showed an advantage of non/never smokers in terms of neoadjuvant chemotherapy complete response rate (HR 0.47, 95% CI 0.29-0.75; p=0.001, I2=0%).
CONCLUSIONS: Smoking status is associated with lower neoadjuvant chemotherapy response rates and higher overall and cancer specific mortality as well as bladder cancer recurrence after radical cystectomy. Appropriate preoperative counseling, together with tightened followup, may have a pivotal role in improving the smoking related long-term survival outcomes in patients with bladder cancer.

Entities:  

Keywords:  cigarette smoking; cystectomy; recurrence; survival; urinary bladder neoplasms

Year:  2020        PMID: 32105187     DOI: 10.1097/JU.0000000000000813

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Prognostic values of distal ureter involvement and survival outcomes in bladder cancer at T1 and T2 stages: a propensity score matching study.

Authors:  Song Xiao; Xiangpeng Zhan; Tao Chen; Jingxin Wu; Linhao Xu; Ming Jiang; Wen Deng; Ke Zhu; Zhenhao Zeng; Xiaofeng Cheng; Qiang Zhou; Wei Huang; Xiaochen Zhou; Cheng Zhang; Bin Fu; Gongxian Wang
Journal:  Int Urol Nephrol       Date:  2022-08-13       Impact factor: 2.266

2.  Current-Smoking-Related COPD or COPD With Acute Exacerbation is Associated With Poorer Survival Following Oral Cavity Squamous Cell Carcinoma Surgery.

Authors:  Jiaqiang Zhang; Wei-Chun Lin; Kuo-Chin Chiu; Szu-Yuan Wu
Journal:  Chronic Obstr Pulm Dis       Date:  2022-04-29

3.  Germline BRCA variants, lifestyle and ovarian cancer survival.

Authors:  Kate Gersekowski; Rachel Delahunty; Kathryn Alsop; Ellen L Goode; Julie M Cunningham; Stacey J Winham; Paul Pharoah; Honglin Song; Susan Jordan; Sian Fereday; Anna DeFazio; Michael Friedlander; Andreas Obermair; Penelope M Webb
Journal:  Gynecol Oncol       Date:  2022-04-07       Impact factor: 5.304

Review 4.  Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.

Authors:  Frederik König; Benjamin Pradere; Nico C Grossmann; Fahad Quhal; Pawel Rajwa; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Takafumi Yanagisawa; Hadi Mostafai; Reza Sari Motlagh; Abdulmajeed Aydh; Roland Dahlem; Shahrokh F Shariat; Michael Rink
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

5.  The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness.

Authors:  Stanley Teleka; Sylvia H J Jochems; Karin Jirström; Tanja Stocks
Journal:  Cancer Med       Date:  2022-03-13       Impact factor: 4.711

6.  A methodologic survey on use of the GRADE approach in evidence syntheses published in high-impact factor urology and nephrology journals.

Authors:  Shuang Zhang; Qi-Jun Wu; Shu-Xin Liu
Journal:  BMC Med Res Methodol       Date:  2022-08-10       Impact factor: 4.612

7.  Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.

Authors:  David D'Andrea; Peter C Black; Homayoun Zargar; Kamran Zargar-Shoshtari; Francesco Soria; Adrian S Fairey; Laura S Mertens; Colin P Dinney; Maria C Mir; Laura-Maria Krabbe; Michael S Cookson; Niels-Erik Jacobsen; Jeffrey S Montgomery; Nikhil Vasdev; Evan Y Yu; Evanguelos Xylinas; Nicholas J Campain; Wassim Kassouf; Marc A Dall'Era; Jo-An Seah; Cesar E Ercole; Simon Horenblas; Srikala S Sridhar; John S McGrath; Jonathan Aning; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeff M Holzbeierlein; Trinity J Bivalacqua; Scott North; Daniel A Barocas; Yair Lotan; Petros Grivas; Andrew J Stephenson; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-08-09       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.